Skip to main content
Midas Edge

Silexion Therapeutics Corp

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

SLXN$0.11-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Shareholders’ Equity (unaudited)

Ordinary shares · Additionalpaid-in Capital · Accumulated deficit · Total shareholders’ equity
Shares · Amount
BALANCE AT JANUARY 1, 202512,323**$2$39,263$(43,254)$(3,989)
CHANGES DURING THE SIX-MONTH PERIOD ENDED JUNE 30, 2025 (unaudited):
Issuance of ordinary shares and warrants upon January offering, net of issuance costs and exercise of pre-funded warrants to ordinary shares (see Note 4(a))24,69534,2524,255
Exercise of warrants upon January Offering (see Note 4(a))4,2701863864
Issuance of ordinary shares and warrants upon January Inducement Offer, net of issuance costs (see Note 4(b))14,81022,8122,814
Share-based compensation3*5858
Conversion of Underwriters Promissory Note1,852*356356
Net loss(4,238)(4,238)
BALANCE AS OF JUNE 30, 202557,953$8$47,604$(47,492)$120
BALANCE AT JANUARY 1, 2026312,665$42$57,727$(55,166)$2,603
CHANGES DURING THE SIX-MONTH PERIOD ENDED JUNE 30, 2026 (unaudited):
Issuance of Ordinary Shares under the At-the-Market Sales Agreement, net of issuance costs (see Note 6(a))450,079611,8791,940
Issuance of ordinary shares and warrants upon warrants inducement, net of issuance costs (see Note 4(c))199,51027802829
Share-based compensation64,2709533542
Conversion of Related Party Promissory Note (see Note 5)153,32021393414
Net loss(6,284)(6,284)
BALANCE AS OF JUNE 30, 20261,179,844$160$61,334$(61,450)$44

All share amounts reflect (when presented as of dates or for periods preceding the relevant reverse share split, on a retroactive basis) 1-for-10 reverse share split effected on May 28, 2026, as discussed in Note 1(d)

** Net of 3 treasury shares held by the Company as of January 1, 2025

F - 6

UNAUDITED CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS’ EQUITY

(U.S. dollars in thousands, except per share data)

Ordinary shares · Additionalpaid-in Capital · Accumulated deficit · Total shareholders’ equity
Shares · Amount
BALANCE AT MARCH 31, 202557,950**$8$47,567$(44,989)$2,586
CHANGES DURING THE THREE MONTHS PERIOD ENDED JUNE 30, 2025 (unaudited):
Share-based compensation3*3737
Net loss(2,503)(2,503)
BALANCE AS OF JUNE 30, 202557,953$8$47,604$(47,492)$120
BALANCE AT MARCH 31, 2026339,486$46$58,144$(57,899)$291
CHANGES DURING THE THREE MONTHS PERIOD ENDED JUNE 30, 2026 (unaudited):
Issuance of Ordinary Shares under the At-the-Market Sales Agreement, net of issuance costs (see Note 6(a))443,671601,8041,864
Issuance of ordinary shares and warrants upon warrants inducement, net of issuance costs (see Note 4(c))199,51027802829
Share-based compensation43,8576191197
Conversion of Related Party Promissory Note (see Note 5)153,32021393414
Net loss(3,551)(3,551)
BALANCE AS OF JUNE 30, 20261,179,844$160$61,334$(61,450)$44

All share amounts reflect (when presented as of dates or for periods preceding the relevant reverse share split, on a retroactive basis) 1-for-10 reverse share split effected on May 28, 2026, as discussed in Note 1(d)

** Net of 3 treasury shares held by the Company as of March 31, 2025

F - 7

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.